Wegener's Granulomatosis
33
1
1
26
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
9.1%
3 terminated out of 33 trials
89.7%
+3.1% vs benchmark
18%
6 trials in Phase 3/4
15%
4 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (33)
Study of One Protein Implicated in Wegener Disease
Vasculitis Pregnancy Registry
Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
Reproductive Health in Men and Women With Vasculitis
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Plasma Exchange for Renal Vasculitis
Anti-Cytokine Therapy for Vasculitis
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
Daclizumab to Treat Wegener's Granulomatosis
Steroids and Methotrexate to Treat Systemic Vasculitis